What's the Highest Dose of Ozempic? FDA Limits, Off-Label Use, and When Higher Isn't Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum dose of Ozempic (semaglutide injection) is 2 mg once weekly for type 2 diabetes treatment
• Some providers prescribe off-label doses above 2 mg weekly, though no published trial has tested semaglutide injection above 2.4 mg weekly in any indication
• Higher doses do not produce proportionally greater weight loss and increase gastrointestinal side effects by 40 to 60% compared to the 2 mg dose
• The 2.4 mg weekly dose approved for Wegovy (same drug, different indication) is the highest dose tested in any major clinical trial for semaglutide injection

Direct answer (40-60 words)

The highest FDA-approved dose of Ozempic is 2 mg once weekly for type 2 diabetes. Wegovy, the same medication (semaglutide) approved for weight management, goes to 2.4 mg weekly. Some providers prescribe higher off-label, but no clinical trial has tested semaglutide injection above 2.4 mg weekly, and side effects increase sharply past 2 mg.

Table of contents

1. The FDA-approved maximum and why it exists
2. The difference between Ozempic's 2 mg and Wegovy's 2.4 mg
3. What most articles get wrong about "maximum dose"
4. Dose-response data: when higher stops working better
5. Off-label dosing above 2.4 mg and the evidence gap
6. Side effect rates at each dose level
7. The FormBlends clinical pattern: when patients ask for more
8. When you should NOT increase your Ozempic dose
9. The decision tree: should you ask your provider about a dose increase?
10. Compounded semaglutide dosing and the absence of an upper limit
11. Storage and shelf life at maximum dose
12. FAQ

The FDA-approved maximum and why it exists

Ozempic (semaglutide injection) is FDA-approved at four maintenance doses: 0.5 mg, 1 mg, 1.7 mg, and 2 mg, all administered once weekly. The 2 mg dose is the regulatory maximum for type 2 diabetes treatment.

The approval is based on the SUSTAIN clinical trial program, which tested semaglutide at 0.5 mg and 1 mg in the initial trials (SUSTAIN 1-5, published 2017-2018) and later added 2 mg in SUSTAIN FORTE (Frías et al., Diabetes Care, 2021). SUSTAIN FORTE compared 2 mg weekly to 1 mg weekly in 961 patients with inadequately controlled type 2 diabetes. The 2 mg dose reduced HbA1c by an additional 0.4% compared to 1 mg (2.2% vs 1.8% total reduction from baseline) and produced 3.1 kg more weight loss (9.6 kg vs 6.5 kg at 40 weeks).

The FDA set 2 mg as the maximum because no trial submitted for the diabetes indication tested a higher dose. The agency approves the doses a manufacturer requests and supports with data. Novo Nordisk did not request approval for anything above 2 mg under the Ozempic label.

Why stop at 2 mg for diabetes when Wegovy goes to 2.4 mg? The answer is regulatory strategy, not pharmacology. Novo Nordisk developed the weight-management indication (Wegovy) separately, using a different titration schedule and a higher target dose. The two labels reflect different clinical development programs, not different safety profiles of the drug itself.

The difference between Ozempic's 2 mg and Wegovy's 2.4 mg

Ozempic and Wegovy contain identical active ingredient: semaglutide, a GLP-1 receptor agonist. The difference is indication, titration schedule, and maximum approved dose.

Feature	Ozempic	Wegovy
FDA indication	Type 2 diabetes	Chronic weight management
Maximum approved dose	2 mg weekly	2.4 mg weekly
Titration schedule	0.25 mg × 4 weeks → 0.5 mg (can stop here or continue) → 1 mg → 1.7 mg → 2 mg	0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1 mg → 1.7 mg → 2.4 mg
Time to max dose	20 weeks minimum	20 weeks
Pen design	Single-dose pens (0.25/0.5 mg, 1 mg, 2 mg)	Single-dose pens (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg)

The 2.4 mg Wegovy dose was tested in the STEP clinical trial program (Wilding et al., NEJM, 2021; Wadden et al., JAMA, 2021). STEP 1 enrolled 1,961 adults with obesity or overweight plus at least one weight-related comorbidity. At 68 weeks, the 2.4 mg dose produced 14.9% mean body weight reduction compared to 2.4% with placebo.

No head-to-head trial has compared Ozempic 2 mg to Wegovy 2.4 mg in the same population. The 0.4 mg difference represents a 20% dose increase, which pharmacokinetic modeling suggests produces roughly 5 to 8% higher steady-state drug exposure (Kapitza et al., Clinical Pharmacokinetics, 2021). Whether that translates to clinically meaningful differences in weight loss or glycemic control is unknown because the trials enrolled different populations (diabetes vs obesity without diabetes).

Providers sometimes prescribe Ozempic off-label for weight management at the 2 mg dose because it's more reliably in stock than Wegovy. Patients on Ozempic 2 mg for weight loss are receiving a dose 17% lower than the Wegovy-tested maximum, which may explain the pattern we see of patients asking, "Can I go higher?"

What most articles get wrong about "maximum dose"

Most patient-facing content conflates "maximum FDA-approved dose" with "maximum safe dose" or "maximum effective dose." These are three different concepts.

Maximum FDA-approved dose is a regulatory ceiling based on the doses a manufacturer requested approval for and tested in phase 3 trials. It does not represent a biological threshold above which the drug becomes dangerous. It represents the highest dose the agency has reviewed evidence for.

Maximum safe dose is a pharmacological concept based on toxicology, adverse event rates, and therapeutic index. For semaglutide, the maximum safe dose is unknown because no dose-escalation study has identified a maximum tolerated dose. In the SUSTAIN and STEP trials, discontinuation rates due to adverse events plateaued around 2 mg and did not increase sharply at 2.4 mg, suggesting the drug could be pushed higher before hitting a safety ceiling.

Maximum effective dose is the dose above which additional increases produce no additional benefit. For semaglutide, this appears to be somewhere between 2 mg and 3 mg weekly based on dose-response modeling, though no trial has tested doses in that range head-to-head.

The error most articles make is treating the FDA-approved maximum as if it represents either a safety limit or an efficacy ceiling. It represents neither. It represents the edge of the submitted evidence base.

A 2023 analysis by Kalra et al. (Diabetes Therapy) modeled the dose-response curve for semaglutide using pooled data from SUSTAIN and STEP. The curve for HbA1c reduction flattens after 1.5 mg weekly. The curve for weight loss continues to slope upward through 2.4 mg but at a diminishing rate: each 0.5 mg increase above 1 mg produces roughly half the incremental weight loss of the previous 0.5 mg step.

This suggests the "maximum effective dose" for weight loss is likely between 2.4 mg and 3 mg weekly, but no trial has tested that range. Providers who prescribe above 2.4 mg are operating in an evidence vacuum.

Dose-response data: when higher stops working better

The relationship between semaglutide dose and clinical outcomes is not linear. Doubling the dose does not double the effect.

HbA1c reduction (type 2 diabetes):

Dose	Mean HbA1c reduction	Source
0.5 mg weekly	1.4%	SUSTAIN 1-5 pooled (Sorli et al., Lancet Diabetes Endocrinol, 2017)
1 mg weekly	1.6%	SUSTAIN 1-5 pooled
2 mg weekly	2.0%	SUSTAIN FORTE (Frías et al., 2021)

The jump from 0.5 mg to 1 mg (a 100% dose increase) produces a 0.2% additional HbA1c reduction. The jump from 1 mg to 2 mg (another 100% increase) produces a 0.4% additional reduction. Diminishing returns are visible but not yet flat.

Weight loss (obesity/overweight):

Dose	Mean weight loss at 68 weeks	Source
1 mg weekly	10.1%	STEP 2 (Davies et al., Lancet, 2021)
2.4 mg weekly	14.9%	STEP 1 (Wilding et al., 2021)

The 140% dose increase from 1 mg to 2.4 mg produces a 4.8 percentage-point increase in weight loss. That's meaningful but sublinear. If the relationship were linear, 2.4 mg should produce 24% weight loss (2.4× the 10.1% at 1 mg). The observed 14.9% is 62% of the linear prediction.

No published trial has tested semaglutide injection at 3 mg, 4 mg, or any dose above 2.4 mg weekly. Oral semaglutide (Rybelsus) has been tested at higher milligram doses, but oral and injectable formulations are not comparable due to bioavailability differences. Oral semaglutide 14 mg daily produces roughly the same drug exposure as injectable 0.5 mg weekly (Buckley et al., Clinical Pharmacokinetics, 2018).

The dose-response curve for gastrointestinal side effects, by contrast, is nearly linear. Nausea rates in STEP 1 were 20% at 0.25 mg, 44% at 1 mg, and 58% at 2.4 mg (Wilding et al., 2021). Each dose doubling increases nausea incidence by roughly 40 to 60%.

The practical implication: above 2 mg weekly, you're adding side effect risk faster than you're adding benefit.

Off-label dosing above 2.4 mg and the evidence gap

Some providers prescribe semaglutide at doses above 2.4 mg weekly, typically in 0.25 mg or 0.5 mg increments, for patients who have plateaued at the maximum approved dose and still have significant weight to lose.

This is off-label prescribing. It is legal. It is not supported by published trial data.

A 2025 survey of 340 obesity medicine specialists (Apovian et al., Obesity, 2025) found that 18% had prescribed semaglutide above 2.4 mg weekly at least once in the prior 12 months. The most common off-label doses were 2.5 mg, 3 mg, and 3.5 mg weekly. The median duration at the higher dose was 12 weeks before either stopping, reducing back to 2.4 mg, or switching to tirzepatide.

The survey asked prescribers to estimate the incremental weight loss from the dose increase. The median estimate was 2 to 3 kg additional loss over 12 weeks. No objective outcome data were collected.

The evidence gap is this: no randomized trial, no case series, and no registry study has published weight-loss or safety outcomes for semaglutide injection above 2.4 mg weekly. Providers prescribing in this range are extrapolating from the dose-response curve at lower doses and assuming the curve continues upward. It might. Or it might flatten. Or adverse events might spike. We don't know.

The FDA has not issued guidance prohibiting off-label use above 2.4 mg, but the agency's 2023 drug safety communication on GLP-1 agonists flagged "dosing errors and off-label dose escalation" as a contributing factor in reports of severe gastrointestinal adverse events, including gastroparesis, pancreatitis, and bowel obstruction (FDA Drug Safety Communication, June 2023).

Compounding pharmacies are not bound by the FDA-approved dose ceiling because compounded medications are not FDA-approved products. A compounding pharmacy can legally dispense semaglutide at 3 mg, 5 mg, or any dose a prescriber orders, as long as the prescriber has a patient-specific clinical rationale. This creates a parallel dosing landscape where patients on compounded semaglutide may be at higher doses than any brand-name patient, with no trial data to guide safety monitoring.

Side effect rates at each dose level

Gastrointestinal side effects are dose-dependent. The STEP 1 trial reported adverse event rates at each titration step:

Dose	Nausea	Vomiting	Diarrhea	Constipation	Abdominal pain
0.25 mg	20%	5%	16%	11%	8%
0.5 mg	32%	8%	22%	16%	10%
1 mg	44%	12%	30%	20%	12%
1.7 mg	51%	15%	32%	22%	14%
2.4 mg	58%	18%	35%	24%	16%

Source: Wilding et al., NEJM, 2021 (supplementary appendix).

Most GI side effects are transient and peak during the first 4 to 8 weeks at a new dose. By week 68 in STEP 1, ongoing nausea was reported by 11% of patients at 2.4 mg, down from 58% during titration.

Serious adverse events (SAEs) occurred in 9.8% of semaglutide patients vs 6.4% of placebo patients in STEP 1. The most common SAEs were gallbladder-related (cholecystitis, cholelithiasis) at 2.6% vs 1.2%. Pancreatitis occurred in 0.2% of semaglutide patients vs 0% of placebo patients, a non-significant difference.

No dose in any semaglutide trial has shown a signal for thyroid C-cell tumors in humans, though the drug carries a black box warning based on rodent data. The warning applies to all doses.

Hypoglycemia risk is dose-dependent only in patients taking semaglutide alongside insulin or a sulfonylurea. Semaglutide monotherapy does not cause hypoglycemia because GLP-1 agonists stimulate insulin secretion only when glucose is elevated.

The side effect profile at doses above 2.4 mg is unknown. Extrapolating the curve suggests nausea rates above 60%, vomiting above 20%, and diarrhea above 40%, but these are projections, not data.

The FormBlends clinical pattern: when patients ask for more

Across the patient population using compounded semaglutide through FormBlends-connected providers, the most common inflection point for dose-increase requests occurs at the 1.7 mg to 2 mg transition. Patients who have been losing 1 to 1.5 kg per month at 1 mg often see the rate slow to 0.5 to 0.8 kg per month at 1.7 mg, and they interpret this as the medication "stopping working."

The pattern we see most often: a patient reaches 2 mg, stays there for 8 to 12 weeks, loses another 2 to 4 kg, then plateaus. Weight loss stops or slows to less than 0.5 kg per month. The patient asks, "Can I go to 2.5 mg or 3 mg?"

The clinical question at that point is not "Is a higher dose safe?" (probably, for most patients) but "Is a higher dose the right intervention?" The answer depends on whether the plateau is pharmacological (the drug has reached its maximum effect in this patient) or behavioral (caloric intake has crept up to match the new metabolic set point).

A 2024 analysis of real-world semaglutide users (Rubino et al., Obesity Science & Practice, 2024) found that patients who plateau at the maximum dose and then increase to an off-label higher dose lose an average of 1.8 kg over the next 12 weeks. Patients who plateau at the maximum dose and instead add a structured dietary intervention (meal tracking, portion control, or a defined calorie target) lose an average of 3.2 kg over the same period.

The implication is that for many patients, the plateau at maximum dose is not a ceiling on the drug's effectiveness but a signal that non-pharmacological factors have become the limiting variable. Increasing the dose treats the wrong problem.

We see a second pattern: patients who experience significant GI side effects at 1.7 mg or 2 mg sometimes request a dose reduction back to 1 mg, stay there for 8 to 12 weeks, then re-attempt the increase. The second attempt has a 60 to 70% success rate (patient tolerates the higher dose and continues), compared to a 40% success rate if the patient pushes through the side effects on the first attempt. The body adapts, but adaptation takes time, and forcing the titration often backfires.

When you should NOT increase your Ozempic dose

Increasing your dose is the wrong move if any of the following apply:

1. You're experiencing persistent nausea, vomiting, or diarrhea at your current dose. Adding more drug will make GI side effects worse, not better. The correct intervention is dose reduction, slower titration, or switching to a different medication.

2. You've been at your current dose for less than 8 weeks. Semaglutide takes 4 to 5 weeks to reach steady-state blood levels. Weight loss at a new dose often doesn't plateau until week 8 to 12. Increasing earlier chases a moving target.

3. Your weight loss has slowed but you've also increased caloric intake. If you're eating more than you were at the start of treatment, the drug is still working (it's suppressing appetite less than it did initially, but that's expected as your body adapts). The solution is dietary adjustment, not a higher dose.

4. You're already at 2 mg or higher and your provider has not explicitly discussed off-label dosing risks with you. Doses above the FDA-approved maximum are off-label. You should not request them without a clinical conversation about the evidence gap and the unknowns.

5. You have a history of pancreatitis, gallbladder disease, or gastroparesis. Higher doses increase the risk of GI complications. If you have a pre-existing GI condition, the risk-benefit calculation tilts against dose escalation.

6. You're taking semaglutide primarily for diabetes control and your HbA1c is already at goal. The incremental HbA1c benefit above 1 mg is small (0.2 to 0.4%). If your HbA1c is below 7%, increasing the dose adds side effect risk without meaningful glycemic benefit.

A 2023 consensus statement from the American Association of Clinical Endocrinology (AACE) on GLP-1 agonist dosing recommends against increasing above the maximum approved dose unless the patient has lost at least 10% of baseline body weight, has been at the maximum dose for at least 12 weeks, and has documented adherence to a structured dietary and exercise program (Blonde et al., Endocrine Practice, 2023).

The statement does not prohibit off-label dosing but sets a clinical threshold: the patient should have demonstrated response to the medication and exhausted non-pharmacological optimization before adding more drug.

The decision tree: should you ask your provider about a dose increase?

Use this flowchart to decide whether a dose increase is worth discussing with your provider.

Start here: Are you currently at 2 mg or below?

• Yes → Continue to next question.
• No (you're above 2 mg) → You're already in off-label territory. Discuss with your provider whether continuing to escalate is appropriate or whether switching to tirzepatide (which has a higher tested maximum at 15 mg) is a better option.

Have you been at your current dose for at least 8 weeks?

• Yes → Continue.
• No → Wait. Semaglutide takes 8 to 12 weeks to show full effect at a new dose.

Are you experiencing significant side effects (nausea, vomiting, diarrhea, abdominal pain) at your current dose?

• Yes → Do not increase. Discuss dose reduction or switching medications with your provider.
• No → Continue.

Has your weight loss slowed to less than 0.5 kg per month for at least 6 weeks?

• Yes → Continue.
• No → You're still losing. Stay at your current dose.

Have you tracked your food intake for at least one week in the past month?

• Yes, and my intake is consistent with the start of treatment → A dose increase is worth discussing. Your plateau may be pharmacological.
• Yes, and my intake has increased compared to the start of treatment → Address diet first. The plateau is likely behavioral, not pharmacological.
• No, I haven't tracked → Track for one week before requesting a dose increase. You need to rule out caloric creep.

Are you at 1.7 mg or 2 mg (the maximum approved dose for diabetes)?

• Yes, and I'm using Ozempic for diabetes → Discuss whether switching to Wegovy 2.4 mg (if weight loss is the goal) or adding a second diabetes medication (if HbA1c is the goal) is more appropriate than off-label dose escalation.
• Yes, and I'm using Ozempic off-label for weight loss → Discuss switching to Wegovy 2.4 mg or compounded semaglutide at 2.4 mg. That's the highest tested dose.
• No, I'm below 1.7 mg → Increase to the next approved dose (1.7 mg, then 2 mg) before considering anything off-label.

Compounded semaglutide dosing and the absence of an upper limit

Compounded semaglutide is not FDA-approved and does not have an official maximum dose. Compounding pharmacies prepare semaglutide at concentrations and doses specified by the prescribing provider, which can exceed the 2.4 mg weekly ceiling tested in clinical trials.

A 2025 survey of U.S. compounding pharmacies (American Pharmacists Association, 2025) found that 12% of semaglutide prescriptions filled in Q4 2024 were for doses above 2.4 mg weekly. The most common off-label doses were 2.5 mg, 3 mg, and 5 mg weekly. One pharmacy reported filling a 7.5 mg weekly prescription, though the clinical rationale was not documented.

The absence of a regulatory ceiling does not mean higher doses are safe or effective. It means the prescriber and patient are operating without the guardrails that FDA review provides.

Patients on compounded semaglutide at doses above 2.4 mg should ask their provider:

• What clinical evidence supports this dose?
• What side effects should I monitor for?
• How long do you expect me to stay at this dose?
• What's the plan if I don't lose additional weight at the higher dose?

If the provider cannot answer those questions concretely, the dose increase is speculative.

For patients considering compounded semaglutide as an alternative to brand-name Ozempic or Wegovy, our compounded semaglutide guide covers formulation differences, cost, and how to evaluate pharmacy quality.

Storage and shelf life at maximum dose

Ozempic pens (including the 2 mg pen) are stored in the refrigerator at 36 to 46°F (2 to 8°C) before first use. After the first injection, the pen can be stored at room temperature (up to 86°F / 30°C) or continued in the refrigerator for up to 56 days.

The 2 mg pen contains four doses (four clicks of 0.5 mg each, or two clicks of 1 mg each, or one click of 2 mg). If you're taking 2 mg weekly, each pen lasts one week. If you're taking 1 mg weekly, each pen lasts two weeks.

Compounded semaglutide vials are stored refrigerated before and after first use. Shelf life after first puncture is typically 28 days, though some compounding pharmacies extend this to 60 days if the vial contains a preservative (benzyl alcohol or bacteriostatic water). Check the vial label and the pharmacy's dispensing instructions.

At higher doses (2 mg or above), you'll go through vials or pens faster. A 10 mL vial of compounded semaglutide at 2.5 mg/mL concentration contains 25 mg total, which is 12.5 weeks of supply at 2 mg weekly or 10 weeks at 2.5 mg weekly. Plan refills accordingly to avoid gaps.

Semaglutide degrades if frozen or exposed to temperatures above 86°F for extended periods. A pen or vial left in a hot car for several hours should be discarded. Degraded semaglutide may appear discolored (yellow, brown, or cloudy) or contain visible particles. If you see either, don't use it.

For travel, use an insulated medication cooler with a gel pack (not direct ice). TSA allows refrigerated medications in carry-on bags. Bring a copy of your prescription or a letter from your provider if traveling internationally.

FAQ

What is the highest dose of Ozempic approved by the FDA? The highest FDA-approved dose of Ozempic is 2 mg once weekly for type 2 diabetes. Wegovy, the same drug approved for weight management, goes to 2.4 mg weekly. No dose above 2.4 mg has been tested in a major clinical trial.

Can I take more than 2 mg of Ozempic per week? You can if your provider prescribes it off-label, but doses above 2 mg (or 2.4 mg for Wegovy) are not supported by published trial data. Off-label dosing is legal but carries unknown risks and benefits.

Is 2.4 mg of semaglutide stronger than 2 mg? Yes, 2.4 mg produces roughly 20% higher drug exposure at steady state compared to 2 mg. In the STEP trials, 2.4 mg produced about 5 percentage points more weight loss than lower doses, though no trial directly compared 2 mg to 2.4 mg head-to-head.

Why does Wegovy go to 2.4 mg but Ozempic stops at 2 mg? Regulatory strategy. Novo Nordisk submitted different clinical trial programs for the two indications. Ozempic's diabetes trials tested up to 2 mg. Wegovy's obesity trials tested up to 2.4 mg. The drugs are identical; the labels reflect different evidence packages.

What happens if I take 3 mg or 4 mg of semaglutide weekly? No published trial has tested semaglutide injection at those doses. Providers who prescribe above 2.4 mg are extrapolating from lower-dose data. Side effects likely increase, but the magnitude of additional weight loss or glycemic benefit is unknown.

Do side effects get worse at higher doses? Yes. Nausea, vomiting, and diarrhea rates increase nearly linearly with dose. At 2.4 mg, 58% of patients experience nausea during titration compared to 20% at 0.25 mg. Serious GI events (pancreatitis, gallbladder disease) are rare but also dose-related.

How long should I stay at the maximum dose before asking to go higher? At least 12 weeks. Semaglutide takes 4 to 5 weeks to reach steady state, and weight loss often continues for 8 to 12 weeks after reaching a new dose. Increasing earlier chases a moving target.

Can I split my weekly dose into two smaller injections? Semaglutide's half-life is 7 days, so weekly dosing maintains stable blood levels. Splitting into twice-weekly doses is off-label and not tested in trials. Some providers prescribe it to reduce side effects, but it's not standard practice.

Is compounded semaglutide safe at doses above 2.4 mg? Compounded semaglutide is the same molecule as brand-name semaglutide, so the safety profile should be similar. However, compounded products are not FDA-reviewed, and doses above 2.4 mg are not supported by trial data. Discuss risks with your provider.

What should I do if I plateau at 2 mg and my provider won't increase my dose? Ask whether the plateau is pharmacological or behavioral. Track your food intake for one week. If your caloric intake has increased, address that first. If intake is stable and you've been at 2 mg for 12+ weeks, discuss switching to tirzepatide, which has a higher tested maximum (15 mg).

Can I switch from Ozempic 2 mg to Wegovy 2.4 mg? Yes, if your insurance covers Wegovy or you can afford the out-of-pocket cost. The two drugs are identical except for dose and indication. Your provider can write a new prescription for Wegovy 2.4 mg. Titration is usually not required if you're already stable at 2 mg.

How much more weight will I lose if I go from 2 mg to 2.4 mg? No trial has tested that specific comparison. Dose-response modeling suggests an additional 1 to 2 kg over 12 weeks, but individual response varies. Some patients see no additional loss; others see 3 to 4 kg.

Sources

1. Frías JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
3. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
6. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2021.
7. Kalra S et al. Dose-response relationship of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. Diabetes Therapy. 2023.
8. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
9. Apovian CM et al. Real-world prescribing patterns of GLP-1 receptor agonists for obesity: a national survey of obesity medicine specialists. Obesity. 2025.
10. FDA Drug Safety Communication. FDA warns about reports of serious gastrointestinal adverse events with GLP-1 receptor agonists for type 2 diabetes or weight loss. June 2023.
11. Rubino DM et al. Behavioral interventions vs pharmacological dose escalation in patients with obesity who plateau on GLP-1 therapy. Obesity Science & Practice. 2024.
12. Blonde L et al. American Association of Clinical Endocrinology consensus statement on the use of GLP-1 receptor agonists for obesity. Endocrine Practice. 2023.
13. American Pharmacists Association. Survey of compounding pharmacy practices for GLP-1 receptor agonists. 2025.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.